Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Conditions
Interventions
Envafolimab+Lenvatinib
Envafolimab
Locations
19
China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Wuhan Union Hospital of China
Wuhan, Hubei, China
Start Date
March 4, 2022
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2025
Last Updated
May 29, 2025
NCT06584032
NCT05077215
NCT01289041
NCT01379534
Lead Sponsor
3D Medicines (Sichuan) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions